BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia
10.1016/j.exphem.2010.11.009
Saved in:
Main Authors: | Jiang, N., Koh, G.S., Suang Lim, J.Y., Yin Kham, S.K., Ariffin, H., Chew, F.T., Juh Yeoh, A.E. |
---|---|
Other Authors: | BIOLOGICAL SCIENCES |
Format: | Article |
Published: |
2014
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/100163 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Identification of prognostic protein biomarkers in childhood acute lymphoblastic leukemia (ALL)
by: Jiang, N., et al.
Published: (2014) -
Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia
by: Soh S.X., et al.
Published: (2018) -
Oxidative Stress in Pediatric Patients with Acute Lymphoblastic Leukemia
by: Phanphen Phoonlapdacha, et al.
Published: (2022) -
Genetic susceptibility to childhood acute lymphoblastic leukemia shows protection in Malay boys: Results from the Malaysia-Singapore ALL Study Group
by: Yeoh, A.E.-J., et al.
Published: (2011) -
Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia
by: Okamoto, R., et al.
Published: (2016)